2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2924

Effect of Antimalarials over the Different Domains of the Damage INDEX in Latin American SLE Patients
Abstract Number: 2925

Economic Evaluation of Damage Accrual in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Abstract Number: 2926

Fucosyltransferase-1 Mediates Macrophage Driven Myofibroblast Differentiation and TGF-β Signaling in Systemic Sclerosis and Bleomycin-Induced Fibrosis
Abstract Number: 2927

Interferon Regulatory Factor (IRF) 7 in Type I IFN Signaling Represents As a Key Upstream Regulator in Early Diffuse SSc Patients and Plays Critical Role in Pathogenesis of Fibrosis
Abstract Number: 2928

STAT3 As an Important Integrator of Profibrotic Pathways in Systemic Sclerosis
Abstract Number: 2929

WNT5A Promotes Tissue Fibrosis By Wnt/PCP-Dependent Activation of Latent TGF-β
Abstract Number: 2930

Transforming Growth Factor Beta 3 (TGFB3) – a Novel Systemic Sclerosis Susceptibility Locus Involved in Fibrosis and Th17 Cell Development Identified By Genome-Wide Association Study in African Americans from the Genome Research in African American Scleroderma Patients Consortium
Abstract Number: 2931

Multi-Organ RNA-Sequencing of Patients with Systemic Sclerosis (SSc) Finds That Intrinsic Subsets Are Conserved across Organ Systems
Abstract Number: 2932

mTOR Pathway Is Activated in Endothelial Cells from Patients with Takayasu Arteritis and Is Modulated By Serum IgG
Abstract Number: 2933

The Microvascular Niche Instructs Pathogenic T Cells in Medium and Large Vessel Vasculitis
Abstract Number: 2934

Comparative Analysis of the Macrophage Glycolytic Machinery in Giant Cell Arteritis (GCA) and in Coronary Artery Disease (CAD)
Abstract Number: 2935

Nasal Microbiota in Patients with Granulomatosis with Polyangiitis Compared to Healthy Controls
Abstract Number: 2936

B-Cell Depletion By Rituximab Affects the Distribution of Effector Th-Cell Subsets in Patients with ANCA Associated Vasculitis
Abstract Number: 2937

Genetic Variants in HLA-C and Class I Pathway Genes Influence Susceptibility to Kawasaki Disease
Abstract Number: 2938

Is Synovial Hypertrophy without Doppler Activity in Rheumatoid Arthritis Joints Sensitive to Change ? – Results of a Longitudinal Ultrasound Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].